Skip to main content
Equibles
OGEN logo

OGEN · Oragenics Inc

Track OGEN — free

Use OGEN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.53 +0.03 (+5.38%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on these factors, there is substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$2.25M
Shares
4.51M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.50 Open$0.51 Day$0.50–0.52 52W close$0.49–1.42 Avg vol 30d32K Short int789K · 17.5% float · 39.1d Short vol12% DataJun 2025–Sep 2026 Filing10-Q · Aug 13

Raw chart and full-history price indicators begin at the captured split on Jun 3, 2025; bars on opposite sides are not compared.

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$37,653
Trailing 12 months
Net income (TTM)
−$10.08M
Trailing 12 months
Revenue growth YoY
-71.4%
Year over year
Operating margin
-55,519.9%
Trailing 12 months
P / E (TTM)
0.4
Trailing earnings · reciprocal yield 222.7%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+505.1%
Year over year · more shares
Price change (1Y)
-53.4%
Trailing year
Short interest
17.5%
Latest settlement · 39.1 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.47
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −28%
below
Price vs 50-day avg −8%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 1%
near low
Momentum
relative strength
Very Weak
1-month return −8%
trailing
6-month return −44%
trailing
YTD return −36%
this year
Relative strength −61%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-18% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
17.49% of float · ▲ +1.0% MoM · 39.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
18 holders — mid 3-yr range
Squeeze score 79
high risk · 0–100
Fundamentals
Weak
Revenue growth −9%
Y/Y
Gross margin 0%
EPS growth +90%
Y/Y
Free cash flow $-9.4M
Quant / Vol
risk profile
Very High
Volatility 69%
annualized · 1-yr
Max drawdown −65%
past year
ATR 5.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−28% Bearish
Price vs 50-day avg
−8% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
1% Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-18% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
17.49% of float · ▲ +1.0% MoM · 39.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
18 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 1% Range high $1
vs 200-day avg -28% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
OGEN
Oragenics Inc
this stock
$2.25M -36.1% -8.9% — 17.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $141.42B +23.1% +46.2% 32.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.84B +9.3% +20.8% 20.9 2.3%
ARGX
Argenx SE
 $64.44B +25.3% — — 1.9%
CSLLY
Csl Ltd
 $59.96B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
18
% held
1.5%
Net QoQ
-122.9K sh
Top holder
GEODE CAPITAL MANAGEMENT,…
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Rising
Shares short
788.9K
Days to cover
39.1d
Change
+7.8K sh
View
Short Volume
Short vol %
12%
As of
Sep 4, 2026
Short Total
View
Fails to Deliver
FTD shares
146
Value
$77
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
62.8%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$37.7K
Net income (FY)
$-9.8M
EPS diluted
$-4.56
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 28, 2026
This year
13
View
Proposed Sales
Value
$22
Shares
66
Filed
Dec 6, 2024
View
Exempt Offerings
Offering
$850.0K
Filed
Aug 8, 2023
View

Performance

Raw-price comparisons begin at the captured split on Jun 3, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
OGEN -6.3% -8.3% -44.0% -2.2% -36.1%
SPY +0.3% +0.6% +16.7% +0.8% +13.4%
vs SPY -6.6% -8.9% -60.7% -3.0% -49.5%
Key facts CIK 1174940 CUSIP 684023609 13F (30d) 15 filings 13 filers Visit website Investor relations